Sign in

Trial result ·

Comparing the response of triple therapy and conventional treatment in male congenital hypogonadotropic hypogonadism: a randomized controlled trial.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This trial looked at adult men born with a hormone condition called CHH. Men were put by chance into groups A, B or C. Group A got hCG, FSH and testosterone together, called triple therapy. Group B got hCG and FSH from the start. Group C got hCG alone first, then FSH was added. The main goals were the doses needed and the time to make sperm.

What they found

More men in group A began making sperm, but this gap was not clear. Group A needed less hCG, with a typical dose of 7500 IU per week. Groups B and C needed 9000 IU per week. Time to sperm was 12 months in groups A and B, and 15 in C. Levels of AMH were alike across the groups. Testis size, hCG dose and Inh B levels helped predict sperm making.

What it means for patients

The authors say triple therapy gave a better quality of life. They say it did not harm sperm making. It also used less hCG than the other plans. They add that AMH and Inh B tests can help track care.

Why it is not certain yet

Both the men and the doctors knew which drugs were given. This open design can sway how people judge results. The gaps in sperm rates and timing could be due to chance. The abstract gives no figures for quality of life. Only adult men with CHH took part.

Source

Comparing the response of triple therapy and conventional treatment in male congenital hypogonadotropic hypogonadism: a randomized controlled trial.

PubMed · PMID 41993983

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Male hypogonadism publications